# case_04_node_2

## Outcome

- Run status: complete; final source: LLM.
- Retrieval found no direct post-osimertinib EGFR L858R evidence for carboplatin+pemetrexed+bevacizumab.
- It found useful regimen-level analogs, including a MET exon 14 first-line case with PFS 14 months and ALK cases with SD.

## Component audit

- Query/plan: correctly separated early efficacy/PFS from toxicity, but the two rounds cost six rerank and four Evidence Review calls.
- Evidence Review: admitted 10/10 items as `analog_support`; four had `target_entity_match=different`, and five had relevance below 0.35. Osimertinib, afatinib, furmonertinib and lorlatinib outcomes are not useful analog support for the target chemotherapy+bevacizumab regimen.
- AnswerMemory: the new atomic fallback worked. It retained 10 separate claims and did not merge populations, drugs or outcomes.
- Safety/Context: preserved the mismatch boundaries; direct findings remained empty and six analog findings were bounded.
- Generate: cited no evidence, which is conservative because no direct claim reached Context. The final prediction therefore came mainly from model prior rather than retrieved support.

## Classification

- General issue candidate: Evidence Review confuses “related clinical fact” with “useful target analog.”
- Code fix candidate: exclude `different` + low relevance from supporting memory.
- Skill candidate only if repeated: compare applicability along regimen, molecular background, line of therapy, CNS setting, outcome and time window before accepting an analogy.
- Confirmed fixed behavior: AnswerMemory atomicity.
